Internal Medicine, Rheumatology · Concord Twp, OH
NPI
1407049133
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7527 Fredle Dr
Concord Twp, OH, 44077
Phone (440) 709-0055
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
174,695 services
Medicare patients, 2024
386
Average age 73
Drug cost, 2024
$4.5M
4,495 prescriptions
Company payments, 2025
$9,832
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by May Azem was code J1602 (injection, golimumab, 1 mg, for intravenous use), 28,450 times for 31 patients. In total May Azem billed 174,695 services in 35 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-10-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 28,450 | 31 | $9.09 | $259K |
| J3247 Injection, secukinumab, intravenous, 1 mg | Office | 25,404 | 26 | $13.76 | $349K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 16,389 | 46 | $24.96 | $409K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 12,600 | 19 | $33.88 | $427K |
| J0897 Injection, denosumab, 1 mg | Office | 5,340 | 57 | $20.49 | $109K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,004 | 12 | $0.23 | $227 |
| 96415 Chemotherapy Administration | Office | 886 | 52 | $20.16 | $18K |
| 96413 Chemotherapy Administration | Office | 754 | 119 | $92.85 | $70K |
| 99214 Office E&M - Established | Office | 688 | 315 | $87.79 | $60K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 332 | 180 | $11.54 | $3,830 |
| 96401 Chemotherapy Administration | Office | 274 | 65 | $51.60 | $14K |
| 99215 Office E&M - Established | Office | 222 | 134 | $125.57 | $28K |
| 96375 Injection Administration | Office | 50 | 11 | $11.18 | $559 |
| 99205 Office E&M - New | Office | 36 | 36 | $160.09 | $5,763 |
| 99213 Office E&M - Established | Office | 22 | 18 | $47.04 | $1,035 |
By year: 2022 $1.8M for 119,734 services; 2023 $1.8M for 131,751 services; 2024 $2.2M for 174,695 services.
Medicare prescription drug claims, 2024
In 2024, the drug May Azem prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 575 prescriptions and refills. In total May Azem wrote 4,495 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 575 | 1,549 | 162 | $24K |
| Methotrexate Methotrexate Sodium | 400 | 943 | 122 | $12K |
| Tramadol Hcl Generic | 377 | 377 | 58 | $4,169 |
| Prednisone Generic | 325 | 547 | 124 | $3,074 |
| Allopurinol Generic | 238 | 622 | 68 | $2,441 |
| Levothyroxine Sodium Generic | 220 | 600 | 66 | $1,977 |
| Gabapentin Generic | 172 | 339 | 43 | $2,257 |
| Methotrexate Sodium Methotrexate Sodium/Pf | 171 | 388 | 64 | $4,193 |
| Folic Acid Generic | 124 | 373 | 39 | $1,227 |
| Enbrel Sureclick Etanercept | 101 | 140 | 16 | $1.1M |
| Xeljanz Xr Tofacitinib Citrate | 96 | 104 | 14 | $613K |
| Leflunomide Generic | 95 | 269 | 31 | $7,188 |
| Duloxetine Hcl Generic | 84 | 236 | 22 | $2,323 |
| Trazodone Hcl Generic | 56 | 133 | 14 | $1,327 |
| Pilocarpine Hcl Generic | 54 | 122 | 17 | $5,839 |
Brand drugs: 804 claims; generic drugs: 3,661 claims; opioid claims: 386.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid May Azem $9,832 ($9,832 in general payments such as food, travel and fees) from 26 companies. The largest payer was Janssen Biotech, Inc. with $3,075.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 16 | $3,075 |
| Mallinckrodt Hospital Products Inc. | 11 | $1,740 |
| Abbvie Inc. ABBV | 30 | $1,331 |
| Amgen Inc. AMGN | 22 | $649 |
| UCB, Inc. UCB.BR | 21 | $480 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $468 |
| E.R. Squibb & Sons, L.L.C. BMY | 21 | $411 |
| ANI Pharmaceuticals, Inc. ANIP | 18 | $264 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $145 |
| Pfizer Inc. PFE | 5 | $141 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.